191 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
"forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation … and fraud litigation, reputational harm, and other consequences.
Governments outside the United States tend to impose strict price controls, which
424B3
SYRE
Spyre Therapeutics Inc.
18 Mar 24
Prospectus supplement
4:06pm
to be conducted.
(k) Litigation. There is no action, suit, proceeding or investigation pending or, to the Company’s Knowledge, currently threatened … Litigation Reform Act of 1995, concerning Spyre and other matters. These forward-looking statements include, but are not limited to, express or implied
8-K
EX-10.1
ag5n8gu3jzn3
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
8-K
EX-99.1
fo93f71wz211y
18 Mar 24
Spyre Therapeutics Announces $180 Million Private Placement
8:31am
POS AM
i3xlo761
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
k5tuzki cztwjl2b4l0i
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
3ddan9 3vqxv7sln2oe
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
424B3
g27fdt14a2
6 Feb 24
Prospectus supplement
9:37pm
8-K
EX-10.1
55jnvq0 zdhiobfrlc6r
5 Feb 24
Entry into a Material Definitive Agreement
7:36am